EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis

Ozge Hurdogan, Safak Mirioglu iD, Egemen Cebeci, Ahmet Burak Dirim, Sidar Bagbudar, Cagla Safak Karaoglan, Ayse Serra Artan iD, Ozgur Akin Oto iD, Isin Kilicaslan, Savas Ozturk iD, Halil Yazici, Yasemin Ozluk iD

Clinical Kidney Journal · 01.05.2026 · 19 (5)

DOI: 10.1093/ckj/sfag138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 30.04.2026. Verfasst von Ozge Hurdogan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Istanbul University, Istanbul Faculty of Medicine Ethical Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fibrillary glomerulonephritis (FGN) is a very rare glomerular disease characterized by non-branching fibril deposition and DNAJB9 positivity. We aimed to analyze our cohort to better elucidate clinicopathologic features and outcomes of patients with FGN.

Methods

Adult patients diagnosed with FGN between 2007 and 2025 and showing DNAJB9 positivity were included. Primary composite outcome was defined as doubling of serum creatinine from baseline, undergoing dialysis or transplantation, development of stage 5 chronic kidney disease or death.

Results

Fifty native kidney biopsies of 44 patients were examined; 17 belonged to males (34%). Most common patterns of injury were mesangial (24, 48%) and membranoproliferative (16, 32%). Mean fibril diameter was 13.7 ± 2.5 nm. Eight biopsies (16%) showed atypical variants such as congophilia, light-chain restriction on frozen immunoflorescence and immunoglobulin G (IgG) negativity. Out of 44 patients, 25 (56.8%) had adequate follow-up data; the mean age was 48.4 ± 12.7 years. Over a median of 27 (7.5–89.5) months, 13 patients (52%) reached primary composite outcome, 10 (40%) underwent kidney replacement therapies and 3 (12%) died. Multivariate logistic regression models showed hemoglobin predicted the primary outcome whereas histopathological features or immunosuppressive use did not. Baseline serum C3 was associated with primary outcome (area under the curve 0.759, 0.525–0.916) with 134 mg/dL as cut-off value. The kidney survival rate was 30.8% in patients with serum C3 ≤134 mg/dL and 87.5% in serum C3 >134 mg/dL. However, multivariate regression models failed to show a clear association between serum C3 levels and primary outcome.

Conclusions

Atypical histopathological features are not uncommon in FGN, complicating the differential diagnosis. Prognosis is still quite dismal despite immunosuppressive use. Lower baseline hemoglobin might indicate poorer outcomes.

Schlagwörter

Stichwörter der Autor:innen

C3DNAJB9electron microscopyfibrillary glomerulonephritisimmunosuppression

Autor:innen und Institutionen

  • Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
  • Division of Nephrology, Istanbul Haseki Training and Research Hospital, Istanbul, Turkey.
  • Department of Pathology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.

ORCID-Profile: Safak Mirioglu, Ayse Serra Artan, Ozgur Akin Oto, Savas Ozturk, Yasemin Ozluk

Förderung

  • Istanbul University
  • Istanbul Faculty of Medicine Ethical Committee

Zitieren

APA

Hurdogan, O., Mirioglu, S., Cebeci, E., Dirim, A. B., Bagbudar, S., Karaoglan, C. S., Artan, A. S., Oto, O. A., Kilicaslan, I., Ozturk, S., Yazici, H., & Ozluk, Y. (2026). Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis. Clinical Kidney Journal, 19(5). https://doi.org/10.1093/ckj/sfag138

Vancouver

Hurdogan O, Mirioglu S, Cebeci E, Dirim AB, Bagbudar S, Karaoglan CS, et al. Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis. Clinical Kidney Journal. 2026;19(5). doi:10.1093/ckj/sfag138

BibTeX
@article{Hurdogan2026,
  author = {Hurdogan, Ozge and Mirioglu, Safak and Cebeci, Egemen and Dirim, Ahmet Burak and Bagbudar, Sidar and Karaoglan, Cagla Safak and Artan, Ayse Serra and Oto, Ozgur Akin and Kilicaslan, Isin and Ozturk, Savas and Yazici, Halil and Ozluk, Yasemin},
  title = {Clinicopathologic features and outcomes of patients with DNAJB9-positive fibrillary glomerulonephritis},
  journal = {Clinical Kidney Journal},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1093/ckj/sfag138}
}
Kostenlos starten →